# Juvensis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/juvensis-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Latest round: Angel (Aug 23, 2022)
- Investors on record: 2

## About

Based in Shanghai, China, and founded in 2021, Juvensis Therapeutics operates as a gene therapy product developer. In March 2025, Juvensis Therapeutics closed a pre-series A funding led by new investor Guofang Fund Management, with participation from other new investors Huntbest Capital, Nanjing Jiangbei New Area Sci-Tech Investment Group, Shanghai Industrial Investment, Summer Capital and returning investor GP Capital.

The company has built a new generation telomere precision modulation technology platform to focus on unmet clinical needs such as heart failure. It has developed the telomere protection protein that can block the vicious cycle of telomere damage and mitochondrial dysfunction, thus promoting the recovery of myocardial function.

The company generates revenue by providing gene therapy products and in vitro cellular products business.

The company will use the funds to advance the clinical development of its core cardiac gene therapy pipeline, JV101, and expand research into heart failure indications.

## Funding rounds

- Angel, Aug 23, 2022 — GP Capital, Shanghai Industrial Investment

## Investors

- GP Capital (https://capitalatlas.ai/funds/gp-capital) — Angel
- Shanghai Industrial Investment (https://capitalatlas.ai/funds/shanghai-industrial-investment) — Angel